Seeking Alpha

More on Novartis/Ophthotech commercialization deal

  • Ophthotech (OPHT) could potentially receive over $1B in milestone and other payments - including the $200M upfront free - during the course of its collaboration with Novartis (NVS) for the commercialization of Forvista, as well as any royalties on sales.
  • Fovista is in a Phase III program consisting of three trials.
  • Ophthotech's shares were +24% premarket. (PR)
  • Previous
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs